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Introduction Prostate cancer is a large clinical burden across Europe. It is, in fact, the most common can-
cer in males, accounting for more than 92,300 deaths annually throughout the continent. Prostate cancer 
is androgen-sensitive; thus an androgen deprivation therapy (ADT) is often used for treatment by reducing  
androgen to castrate levels. Several ADT agents have achieved benefits with effective palliation, but, 
unfortunately, severe adverse events are frequent. Contemporary ADT (Luteinising Hormone Releasing 
Hormone agonist - LHRHa injections) can result in side effects that include osteoporosis and fractures, 
compromising quality of life and survival. 
Methods In this review we analysed the associated bone toxicity consequent upon contemporary ADT  
and based on the literature and our own experience we present future perspectives that seek to mitigate 
this associated toxicity both by development of novel therapies and by better identification and prediction 
of fracture risk.
Results Preliminary results indicate that parenteral oestrogen can mitigate associated osteoporotic risk 
and that CT scans could provide a more accurate indicator of overall bone quality and hence fracture risk. 
Conclusions As healthcare costs increase globally, cheap and effective alternatives that achieve ADT, but 
mitigate or avoid such bone toxicities, will be needed. More so, innovative techniques to improve both the 
measurement and the extent of this toxicity, by assessing bone health and prediction of fracture risk, are 
also required.
Corresponding author
Hannah Wilson
Imperial College London
Charing Cross Hospital
Fulham Palace Road
W6 8RF London, UK 
phone: 07 881 765 605
hcw112@ic.ac.uk
Key Words: prostate cancer ‹› androgen deprivation therapy ‹› luteinising hormone releasing hormone 
agonist ‹› osteoporosis ‹› fracture imaging
Cent European J Urol 2015; 68: 165-168 doi: 10.5173/ceju.2015.513
INTRODUCTION
The discovery by Huggins in the 1940s that pros-
tate cancer is androgen-sensitive led to the devel-
opment of therapies, with differing mechanisms 
of action, to achieve castrate levels of androgen 
(ADT). Unfortunately, these agents often also had 
major unwanted side effects, such as osteoporosis 
and fractures, with ADT achieved with contem-
porary LHRH agonists (LHRHa) [1]. As both the 
clinical and financial burden surrounding prostate 
cancer grows [2], cheap and effective alternatives 
that achieve ADT but mitigate such bone toxicities 
are required. 
Mechanisms of action and toxicity  
with contemporary hormonal treatment  
of prostate cancer
Prostate cancer cell growth is usually androgen-de-
pendent [3], through stimulation of androgen recep-
tors for growth and proliferation [4]. ADT in men, ei-
ther medically (LHRHa) or by surgical orchiectomy, 
suppresses serum concentrations of both androgens 
and oestrogen to less than 5% and 20% of normal val-
ues respectively (oestradiol is synthesised in males 
by the aromatisation of testosterone) [5]. These very 
low sex hormone levels result in potentially major 
toxicities, including hot flushes, sarcopenia, erectile 
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dysfunction and osteoporosis (the latter and related 
fragility fracture risk specifically are most likely 
a consequence of oestrogen deficiency) [6].
Osteoporosis, fracture risk and ADT
Susceptibility to bone fractures arises following 
an imbalance in the activity of cells involved in bone 
turnover, namely osteoblasts and osteoclasts [7]. This 
results in reduced bone formation with increased 
bone resorption. As such, bone mineral density 
(BMD) is reduced and susceptibility to bone fracture 
increases. Following initiation of ADT, accelerated 
bone resorption ensues, leading to both a reduced 
bone mass, as well as structural changes with perfo-
ration of trabeculae [8] accounting, therefore, for the 
greater risk of developing osteoporosis [9]. Shahin-
ian et al. demonstrated a direct link between ADT 
and  fracture risk [10], whilst Shao et al. confirmed 
this and reported it to be directly proportional to the 
number of LHRHa doses received [11]. Importantly, 
Shao et al. reported that if a fracture occurred, it was 
associated with an overall 40% higher relative risk 
of mortality compared to if no fracture occurred 
(mortality was 6.27% higher within 6 months and 
9.87% within 12 months of experiencing a fracture). 
There is, therefore, an unmet need for new and ef-
fective alternative interventions that achieve ADT, 
but avoid bone toxicities and the related morbidity, 
mortality and cost.
Alternative therapies: revisiting the past
Oral oestrogen (diethylstilbestrol – DES) was origi-
nally one of the main therapeutic options for treat-
ing prostate cancer. While many studies confirmed 
its efficacy of androgen suppression, and even im-
proved overall survival, thorough analyses revealed 
it was associated with life-threatening cardiovas-
cular toxicity [12]. Importantly, these early studies 
were conducted using a relatively high dose of DES 
(5 mg) and further work has elucidated that a lower 
dose, either 3 mg or 1 mg may avoid or reduce such 
cardiovascular toxicity [13, 14]. This is now known 
to be due directly to the hepatic first-pass of oes-
trogen, which results in induction of pro-coagulant 
proteins increasing the risk of thromboembolism 
and cardiovascular events. More recently, there 
is evidence that parenteral administration of oestro-
gen (either by intramuscular injection or transcu-
taneously) is able to circumvent this cardiovascular 
toxicity [15, 16]. Furthermore, the administration 
of parenteral (exogenous) oestrogen returns serum 
(endogenous) oestrogen to levels that may miti-
gate contemporary ADT toxicities that are caused 
by endogenous oestrogen depletion. Such mitiga-
tions of toxicities include osteoporosis, by improving 
the BMD [17].
New and encouraging preliminary data reveals oes-
trogen to be a cheap and safe option. Moreover with 
outcomes at least equivocal to contemporary ADT, 
the question of why oestrogen in parenteral form has 
yet to reclaim a role in prostate cancer therapy, re-
mains a mystery. The ongoing UK National PATCH 
(Prostate Adenocarcinoma TransCutaneous Hor-
mones) randomised clinical trial comparing transder-
mal oestradiol with LHRHa in locally advanced and 
metastatic prostate cancer has shown preliminary 
data to support the potential offered by oestrogen to 
deliver ADT and mitigate associated bone toxicity, as 
well as other adverse events of LHRHa ADT [18]. 
PATCH, which includes a total of 686 men, compares 
oestrogen patches (EP; FemSeven 100 µg/24 hr, 
4 patches changed twice-weekly reducing to 3 after 
4 weeks) versus LHRHa for locally advanced or met-
astatic prostate cancer (allocation ratio 2:1 before 
21/2/2011, 1:1 after).  Early Phase II data showed 
equivalence of safety and efficacy between trial 
arms [15]. A recent PATCH sub-study evaluating 
bone health further highlighted the osteoprotective 
potential of transdermal oestrogen whilst avoiding 
the associated cardiovascular toxicity of oral oes-
trogen. Compared to baseline, lumbar spine BMD 
declined following LHRHa treatment at both year 
1 and year 2 (-2.11% and -6.09% respectively), while 
it increased with oestrogen patch treatment at year 
1 (+6.43%) and was maintained at year 2 (+4.58). 
These early results encourage the hypothesis that 
exogenous oestrogen suppresses testosterone to cas-
trate levels whilst appearing to improve BMD values 
(Table 1) [17].
Predicting fracture risk: is the current gold 
standard accurate enough?
The current gold standard for measuring osteoporot-
ic risk is assessment of BMD [19], This is assessed 
*Comparing arms
Table 1. Early data from the bone sub-study of the PATCH trial: 
Changes in lumbar spine bone mineral density at 1 and 2 years 
from baseline (Langley et al. 2014 [17])
Mean percentage change p-value
LHRHa arm
Transdermal oestrogen 
arm
Year 1 -2.11% (n=21) +6.43%, (n=39) <0.001*
Year 2 -6.09%, n=10 +4.58%, n=20 <0.001*
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using Dual Energy X-ray Absorptiometry (DEXA) 
and the diagnostic tool: Fracture Risk Assess-
ment Tool (FRAX) [20]. FRAX integrates the BMD 
of the femoral neck along with multiple clinical risk 
factors to calculate both the 10-year probability 
of a hip fracture and a major osteoporotic fracture 
[21]. Whilst originally it was thought that bone 
strength was almost entirely explained by density, 
clinical observations did not support the data [22]. 
It was subsequently found that densitometry failed 
to take into account the importance of cortical geom-
etry and trabecular architecture for bone strength. 
In fact, BMD only accounts for about 40–50% of the 
in vitro compressive strength of bone, whilst struc-
ture contributes as much as 30–40% of the remainder 
[23]. Following these discoveries, a new understand-
ing of bone strength-termed bone quality, operation-
ally defined as the structural and mechanical basis of 
bone strength, was developed [24]. 
Bone quality is an amalgamation of all the factors 
that determine how well a skeleton can resist frac-
turing, including the micro-architecture, accumu-
lated microscopic damage, quality of collagen, size of 
mineral crystals and the rate of bone turnover [19]. 
The current challenge is to find a suitable and non-
invasive method of measuring bone quality in clinical 
practice, which can predict the risk of bone fracture 
in individual patients. Whilst advanced technologies 
such as computerised tomography (CT) and magnet-
ic resonance imaging (MRI) have been considered, 
it is difficult to balance factors such as radiation risk 
to the patient, technical matters including image 
resolution and the inescapable costs of healthcare.
CONCLUSIONS
There is an unmet need to improve management 
of patients requiring treatments that may diminish 
bone quality, as well as instruments that will pre-
dict this, and hence osteoporotic and fracture risk to 
patients. This is particularly important for those al-
ready at an increased risk of bone loss, including the 
elderly or prostate cancer patients undergoing ADT. 
Patients enrolled on the PATCH trial offer a unique 
opportunity to study these bone quality changes 
by comparing directly between prostate cancer ther-
apies that either decrease (LHRHa) or increase (oes-
trogen) bone quality, and thus to assess the methods 
by which these changes may be more easily moni-
tored and speedily diagnosed. 
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